Shc3 is also required for the drug resistance breast cancer cells by mediating nuclear translocation of ErbB2, thereby facilitating P‐gp expression by promoting ErbB2‐COX2‐MDR1 axis activity. This evidence concerns the gene ERBB2 and breast carcinoma.